These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8067772)

  • 1. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.
    Mouton JW; den Hollander JG
    Antimicrob Agents Chemother; 1994 May; 38(5):931-6. PubMed ID: 8067772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
    J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.
    Nicolau DP; Nightingale CH; Banevicius MA; Fu Q; Quintiliani R
    Antimicrob Agents Chemother; 1996 Jan; 40(1):61-4. PubMed ID: 8787880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.
    Loo AS; Neely M; Anderson EJ; Ghossein C; McLaughlin MM; Scheetz MH
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5854-9. PubMed ID: 24018264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.
    Girardi C; Tonnellier M; Goldstein I; Sartorius A; Wallet F; Rouby JJ;
    Intensive Care Med; 2006 Dec; 32(12):2042-8. PubMed ID: 16858611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
    Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
    Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro.
    Barclay ML; Begg EJ; Chambers ST; Boswell DR
    Antimicrob Agents Chemother; 1995 Jan; 39(1):132-6. PubMed ID: 7695294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.
    Burgess DS; Hastings RW; Hardin TC
    Clin Ther; 2000 Jan; 22(1):66-75. PubMed ID: 10688391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa.
    Moore KW; Trepanier LA; Lautzenhiser SJ; Fialkowski JP; Rosin E
    Am J Vet Res; 2000 Oct; 61(10):1204-8. PubMed ID: 11039548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Landersdorfer CB; Hüttner SJ; Drusano GL; Kinzig M; Holzgrabe U; Stephan U; Sörgel F
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1275-82. PubMed ID: 20065059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
    den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
    Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.
    Ferrari F; Lu Q; Girardi C; Petitjean O; Marquette CH; Wallet F; Rouby JJ;
    Intensive Care Med; 2009 Oct; 35(10):1792-800. PubMed ID: 19652947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion of ceftazidime with an elastomeric infusion device.
    Couldry R; Sanborn M; Klutman NE; Strayer AH
    Am J Health Syst Pharm; 1998 Jan; 55(2):145-9. PubMed ID: 9465978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa.
    Cojutti PG; Maximova N; Schillani G; Hope W; Pea F
    J Antimicrob Chemother; 2019 Jun; 74(6):1648-1655. PubMed ID: 30838391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronokinetics of ceftazidime after intramuscular administration to dogs.
    Monfrinotti A; Ambros L; Montoya L; Prados AP; Rebuelto M
    Chronobiol Int; 2010 May; 27(3):549-59. PubMed ID: 20524800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    Blaser J; Stone BB; Groner MC; Zinner SH
    Antimicrob Agents Chemother; 1985 Jul; 28(1):64-8. PubMed ID: 3929682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.